Purchase this article with an account.
C. Shima, H. Sakaguchi, S. Kusaka, M. Kamei, Y. Ikuno, M. Sawa, M. Tsujikawa, Y. Oshima, F. Gomi, Y. Tano; Systemic and Ocular Adverse Events Following Intravitreal Injection of Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1819. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the systemic and ocular adverse events, following intravitreal injection of bevacizumab, for the treatment of diseases associated with vascular endothelial growth factor.
386 patients who visited to the Osaka University Hospital, Osaka, Japan and received intravitreal injection of bevacizumab were enrolled in this study. Approval from the Institutional Review Board Committee and informed consent were obtained for all cases. The systemic and ocular complications which occurred within 2 months after each intravitreal injection of bevacizumab were retrospectively reviewed.
There were 4 systemic (1.0%) and 3 intraocular (0.8%) adverse events. Systemic complications were all menstrual disorders. Menstrual disorder was found in 3 out of 8 cases (37.5%) from patients in their 20s, and 1 out of 12 cases (8.3%) from patients in their 30s. Three patients had atypical genital bleeding which continued for more than 1 month, and three patients had loss of their menstrual periods for greater than 2 months. Ocular complications included 1 retinal pigment epithelial tear and 2 chemosis.
Intravitreal injection of bevacizumab has a possibility of causing systemic, as well as intraocular adverse events.
This PDF is available to Subscribers Only